NDA 215500 · Uswm
Iwilfin
Eflornithine Hydrochloride · Oral
Breakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Nov 26, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Dec 13, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
53
11 Phase 3, 11 recruiting
FAERS reports
42
31 serious, 13 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 26, 2026.
IWILFIN (eflornithine) is indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy. IWILFIN is an ornithine decarboxylase inhibitor indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy. ( 1 )
Mechanism: Eflornithine is an irreversible inhibitor of the enzyme ornithine decarboxylase (ODC), the first and rate-limiting enzyme in the biosynthesis of polyamines and a transcriptional target of MYCN . Polyamines are involved in differentiation and proliferation of mammalian cells and are important for neoplastic transformation. Inhibition of polyamine synthesis by eflornithine restored the balance of the LIN28/Let-7 metabolic pathway, which is involved in regulation of cancer stem cells and glycolytic metabolism, by decreasing expression of the oncogenic drivers MYCN and LIN28B in MYCN -amplified...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 13, 2023 Original approval · Type 5 - New Formulation or New Manufacturer · priority review Breakthrough therapyOrphanLetterLabelReview
1 products under this application
- IWILFIN · EFLORNITHINE HYDROCHLORIDE EQ 192MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Eflornithine" as an intervention, any sponsor and status, largest first.
Drugs for Neglected DiseasesAcademic, hospital or other
NCT00906880 · 630 participants · Start Apr 2009 · Primary completion Sep 2010
Drug: Nifurtimox-Eflronithine Combination Treatment (NECT) · For: Human African Trypanosomiasis
Sites: Bandundu, Republic of the Congo; Kwamouth, Republic of the Congo; Yasa Bonga, Republic of the Congo · 6 sites in all
- Pediatric Precision Laboratory Advanced Neuroblastoma TherapyPivotal-lookingRecruiting
Giselle ShollerAcademic, hospital or other
NCT02559778 · 500 participants (planned) · Start Sep 2015 · Primary completion Sep 2030
Drug: Ceritinib; dasatinib and 3 more · For: Neuroblastoma
Sites: Birmingham, Alabama; Little Rock, Arkansas; Oakland, California · 28 sites in all
- Eflornithine in Treating Patients With Bladder CancerPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00003814 · 450 participants (planned) · Start Feb 1999
Drug: eflornithine · For: Bladder Cancer
Sites: Birmingham, Alabama; Huntsville, Alabama; Anaheim, California · 61 sites in all
- Neuroblastoma Maintenance Therapy TrialActive, not recruiting
Giselle ShollerAcademic, hospital or other
NCT02679144 · 441 participants (planned) · Start Feb 2016 · Primary completion Feb 2028
Drug: Difluoromethylornithine (DFMO) · For: Neuroblastoma
Sites: Birmingham, Alabama; Little Rock, Arkansas; Oakland, California · 46 sites in all
- Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African TrypanosomiasisPivotal-lookingTerminated
EpicentreAcademic, hospital or other
NCT00330148 · 435 participants · Start Mar 2001
Drug: melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d; melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d and 1 more · For: Trypanosomiasis, African
Sites: Omugo, Uganda
Milton S. Hershey Medical CenterAcademic, hospital or other
NCT07321912 · 406 participants (planned) · Start Jun 5, 2026 · Primary completion Jun 1, 2031
Drug: Eflornithine; Topotecan and 7 more · For: Osteosarcoma; Ewing Sarcoma
Sites: Tampa, Florida; Portland, Oregon; Hershey, Pennsylvania
- Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2Pivotal-lookingCompleted
Drugs for Neglected DiseasesAcademic, hospital or other
NCT01685827 · 394 participants · Start Oct 2012 · Primary completion Nov 11, 2016
Drug: Fexinidazole; Nifurtimox and 1 more · For: Human African Trypanosomiasis (HAT); Sleeping Sickness
Sites: Batangafo, Central African Republic; Bagata, Democratic Republic of the Congo; Masi Manimba, Republic of the Congo · 10 sites in all
- Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon PolypsPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00118365 · 375 participants · Start Jul 1998 · Primary completion Aug 2008
Drug: eflornithine; sulindac · For: Precancerous Condition
Sites: Orange, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death7
- deafness6
- alopecia5
- condition aggravated5
- disease progression4
- neuroblastoma4
- disease recurrence2
- dry mouth2
- eyelash changes2
- joint dislocation2
- motor developmental delay2
- off label use2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 18 |
| 2025 | 6 |
| 2026 | 6 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons.
Oesterheld J, Ferguson W, Kraveka JM, et al. · J Clin Oncol 2024 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- Hirsutism: an evidence-based treatment update.
Somani N, Turvy D · Am J Clin Dermatol 2014 · Systematic Review
- Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis.
Burke CA, Dekker E, Lynch P, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Comparative Study
- Chemotherapy for second-stage human African trypanosomiasis: drugs in use.
Lutje V, Probyn K, Seixas J, et al. · Cochrane Database Syst Rev 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.
Colman H, Lombardi G, Wong ET, et al. · J Clin Oncol 2026 · Clinical Trial, Phase III, Randomized Controlled Trial
- Eflornithine for chemoprevention in the high-risk population of colorectal cancer: a systematic review and meta-analysis with trial sequential analysis.
Yang L, Wang Y, Hu S, et al. · Front Oncol 2023 · Systematic Review
Sponsor: Uswm
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.